Is 722 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 722 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 722's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 722's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 722?
Key metric: As 722 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 722. This is calculated by dividing 722's market cap by their current
revenue.
What is 722's PS Ratio?
PS Ratio
7.5x
Sales
CN¥56.07m
Market Cap
CN¥419.05m
722 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 722 is expensive based on its Price-To-Sales Ratio (7.5x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is 722's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
722 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
7.5x
Fair PS Ratio
20.1x
Price-To-Sales vs Fair Ratio: 722 is good value based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (20.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 722 forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€0.051
€0.20
+289.1%
5.3%
€0.21
€0.19
n/a
2
Dec ’25
€0.051
€0.20
+281.6%
5.3%
€0.21
€0.19
n/a
2
Nov ’25
€0.07
€0.20
+180.7%
5.3%
€0.21
€0.19
n/a
2
Oct ’25
€0.06
€0.20
+227.5%
5.3%
€0.21
€0.19
n/a
2
Sep ’25
€0.044
€0.19
+340.9%
4.3%
€0.20
€0.19
n/a
2
Aug ’25
€0.035
€0.21
+504.2%
11.9%
€0.24
€0.19
n/a
2
Jul ’25
€0.063
€0.21
+238.5%
11.5%
€0.24
€0.19
n/a
2
Jun ’25
€0.093
€0.21
+128.1%
11.5%
€0.24
€0.19
n/a
2
May ’25
€0.095
€0.21
+124.5%
11.5%
€0.24
€0.19
n/a
2
Apr ’25
€0.096
€0.21
+122.1%
11.5%
€0.24
€0.19
n/a
2
Mar ’25
€0.12
€0.50
+315.4%
48.0%
€0.74
€0.26
n/a
2
Feb ’25
€0.13
€0.50
+292.5%
48.0%
€0.74
€0.26
n/a
2
Jan ’25
€0.21
€0.51
+149.9%
43.7%
€0.74
€0.29
n/a
2
Dec ’24
€0.23
€0.51
+127.8%
43.7%
€0.74
€0.29
€0.051
2
Nov ’24
€0.16
€0.54
+231.2%
34.6%
€0.74
€0.29
€0.07
3
Oct ’24
€0.13
€0.54
+331.1%
34.6%
€0.74
€0.29
€0.06
3
Sep ’24
€0.12
€0.66
+434.9%
8.2%
€0.73
€0.60
€0.044
3
Aug ’24
€0.15
€0.74
+383.7%
18.6%
€0.93
€0.60
€0.035
3
Jul ’24
€0.16
€0.80
+401.1%
17.7%
€0.96
€0.63
€0.063
4
Jun ’24
€0.20
€0.80
+300.9%
17.7%
€0.96
€0.63
€0.093
4
May ’24
€0.28
€0.80
+190.5%
17.7%
€0.96
€0.63
€0.095
4
Apr ’24
€0.30
€0.87
+190.8%
13.4%
€0.97
€0.71
€0.096
3
Mar ’24
€0.46
€1.19
+155.4%
38.2%
€1.81
€0.76
€0.12
3
Feb ’24
€0.62
€1.20
+93.7%
40.1%
€1.87
€0.75
€0.13
3
Jan ’24
€0.60
€1.20
+100.2%
40.1%
€1.87
€0.75
€0.21
3
Dec ’23
€0.47
€1.30
+176.8%
42.6%
€1.85
€0.75
€0.23
2
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.